2396
J. Am. Chem. Soc. 1997, 119, 2396-2403
Crystal Structures of Oligodeoxyribonucleotides Containing
6′-R-Methyl and 6′-R-Hydroxy Carbocyclic Thymidines†
Stefan Portmann,‡,§ Karl-Heinz Altmann,| Nathalie Reynes,|, and Martin Egli*,‡
Contribution from the Department of Molecular Pharmacology and Biological Chemistry,
Northwestern UniVersity Medical School, Chicago, Illinois 60611-3008, Organic Chemistry
Laboratory, ETH Swiss Federal Institute of Technology, CH-8092 Zu¨rich, Switzerland, and
Central Research Laboratories, CIBA Ltd., CH-4002 Basel, Switzerland
ReceiVed July 12, 1996X
Abstract: The X-ray crystal structures of two self-complementary DNA duplexes with the sequence
d(CGCGAAtMe/OH Me/OHCGCG) containing four 6′-R-methyl (tMe) or four 6′-R-hydroxy carbocyclic thymidines (tOH),
t
respectively, have been determined. Both structures are isomorphous to the native Dickerson-Drew dodecamer
duplex [d(CGCGAATTCGCG)]2. The cyclopentane moieties of the modified carbocyclic thymidine residues lacking
the deoxyribose 4′-oxygen adopt either C2′-endo or C1′-exo B-DNA type puckers. The dodecamer duplex
incorporating 6′-R-methyl carbocyclic thymidines shows an enlarged minor groove relative to both the unmodified
duplex and the one with incorporated 6′-R-hydroxy carbocyclic thymidines. The pairing of oligonucleotides containing
single or multiple 6′-R-substituted carbocyclic thymidines with complementary DNA is discussed on the basis of the
structural data.
Introduction
structure that are associated with covalent modification of the
sugar-phosphate backbone of one of the component strands.3-6
Changes in the ssRNA- or DNA-binding affinity of modified
oligonucleotides do not necessarily have to reflect, or at least
not exclusively so, structural changes in the Watson-Crick
duplex but could also be related to conformational changes in
the single strand.7,8 However, it is very likely that any changes
in the duplex structure that do actually occur will also affect
duplex stability. The structural characterization of modified
DNA/DNA and DNA/RNA duplexes should, therefore, not only
improve our basic understanding of the structural properties of
nucleic acid duplexes in general but it might also lead to the
design of novel modifications with more favorable properties
for therapeutic applications.
In this context we have embarked on a comprehensive
program directed at the crystallographic investigation of nucleic
acid duplexes incorporating sugar- and backbone-modified
component strands. As part of these continuing studies, we now
report on the structural properties of two modified analogs of
the Dickerson-Drew dodecamer d(CGCGAATTCGCG), where
both thymidine residues have been replaced either by 6′-R-
Inhibition of protein synthesis by the sequence-specific
binding of an oligonucleotide to single-stranded (ss) RNA or
double-stranded (ds) DNA targets (“antisense” and “antigene”
approach, respectively) in the recent past has developed into
an important novel approach in modern drug design.1 Due to
the insufficient metabolic stability of natural DNA and RNA
under physiological conditions, the successful implementation
of such oligonucleotide-based drug design strategies depends
on the availability of chemically modified oligonucleotides or
oligonucleotide analogs. These must not only exhibit largely
increased resistance to nucleolytic degradation but also retain
the ability to bind to their complementary target nucleic acids
with high affinity and in a highly sequence-specific manner.1
As a consequence, a large variety of structurally modified
oligonucleotide analogs have become known over the last few
years and the effects of such structural modifications on nuclease
resistance and RNA- or DNA-binding affinity have been
investigated in some detail.1,2 However, in contrast to the wealth
of RNA- or DNA-binding data that have emerged from those
studies, far less information is available on the changes in duplex
(3) For NMR spectroscopic studies on duplexes incorporating formacetal-
and amide-type backbone modifications, respectively, cf.: (a) Gao, X.; Jeffs,
P. W. J. Biomol. NMR 1994, 4, 17-34 (formacetal). (b) Blommers, M. J.
J.; Pieles, U.; De Mesmaeker, A. Nucleic Acids Res. 1994, 22, 4187-4194
(amide).
(4) For structural studies on duplexes incorporating peptide nucleic acids
(PNA) strands, cf.: (a) Brown, S. C.; Thomson, S. A.; Veal, J. M.; Davis,
D. G. Science 1994, 265, 777-780. (b) Betts, L.; Josey, J. A.; Veal, J. M.;
Jordan, S. R. Science 1995, 270, 1838-1841.
(5) For X-ray crystallographic studies of self-complemenatry DNA
duplexes containing 2′-O-methyladenosine and 4′-thiothymidine, respec-
tively, cf.: (a) Lubini, P.; Zu¨rcher, W.; Egli, M. Chem. & Biol. 1994, 1,
39-45 (2′-O-methyl ribose modification). (b) Boggon, T. J.; Hancox, E.
L.; McAuley-Hecht, K. E.; Connolly, B. A.; Hunter, W. N.; Brown, T.;
Walker, R. T.; Leonard, G. A. Nucleic Acids Res. 1996, 24, 951-961 (4′-
thio modification).
* Author to whom correspondence should be addressed: MP&BC
Department, Northwestern University Medical School; Phone (312) 503-
0845; Fax (312) 503-0796; E-mail m-egli@nwu.edu.
† Coordinates for both crystal structures have been deposited in the
Nucleic Acid Data Base; entry codes NDBS79 (MEME) and NDBS80
(OHOH).
‡ Northwestern University Medical School.
§ ETH Swiss Federal Institute of Technology.
| CIBA, Ltd.
Summer Student from April to July 1994.
X Abstract published in AdVance ACS Abstracts, February 15, 1997.
(1) (a) Uhlmann, E.; Peyman, A. Chem. ReV. 1990, 90, 543-584. (b)
Milligan, J. F.; Matteucci, M. D.; Martin, J. C. J. Med. Chem. 1993, 36,
1923-1937. (c) Antisense Research and Applications; Crooke, S. T., Lebleu,
B., Eds.; CRC Press, Inc.: Boca Raton, FL, 1993. (d) Altmann, K.-H.;
Dean, N. M.; Fabbro, D.; Freier, S. M.; Geiger, T.; Ha¨ner, R.; Hu¨sken, D.;
Martin, P.; Monia, B. P.; Mu¨ller, M.; Natt, F.; Nicklin, P.; Phillips, J.; Pieles,
U.; Sasmor, H.; Moser, H. E. Chimia 1996, 50, 168-176.
(2) (a) Varma, R. S. Synlett 1993, 621-637. (b) De Mesmaeker, A.;
Ha¨ner, R.; Martin, P.; Moser, H. E. Acc. Chem. Res. 1995, 28, 366-374.
(c) De Mesmaeker, A.; Altmann, K.-H.; Waldner, A.; Wendeborn, S. Curr.
Opin. Struct. Biol. 1995, 343-355.
(6) Recent X-ray crystal structure determinations of chemically modified
oligonucleotide analogs have been reviewed Egli, M. Angew. Chem., Int.
Ed. Engl. 1996, 35, 1894-1909.
(7) Schmit, C.; Be´vierre, M.-O.; De Mesmaeker, A.; Altmann, K.-H.
Bioorg. Med. Chem. Lett. 1994, 4, 1969-1974.
(8) Altmann, K.-H.; Imwinkelried, R.; Kesselring, R.; Rihs, G. Tetra-
hedron Lett. 1994, 35, 7625-7628 and references cited therein.
S0002-7863(96)02406-7 CCC: $14.00 © 1997 American Chemical Society